The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injury.
Wei Ruan,Tao Li,Jaewoong Lee,In Hyuk Bang,Wankun Deng,Xinxin Ma,Seung-Hee Yoo,Boyun Kim,Jiwen Li,Xiaoyi Yuan,Yu A An,Yin-Ying Wang,Yafen Liang,Matthew Deberge,Dongze Zhang,Zhen Zhou,Yanyu Wang,Josh Gorham,Jonathan G Seidman,Christine E Seidman,Sary F Aranki,Ragini Nair,Lei Li,Jagat Narula,Zhongming Zhao,Alemayehu G Abebe,Jochen Daniel Muehlschlegel,Kuang-Lei Tsai,Holger K Eltzschig
DOI: https://doi.org/10.21203/rs.3.rs-3938716/v1
2024-01-01
Abstract:Acute myocardial infarction stands as a prominent cause of morbidity and mortality worldwide1-6. Clinical studies have demonstrated that the severity of cardiac injury following myocardial infarction exhibits a circadian pattern, with larger infarct sizes and poorer outcomes in patients experiencing morning onset myocardial infarctions7-14. However, the molecular mechanisms that govern circadian variations of myocardial injury remain unclear. Here, we show that BMAL114-20, a core circadian transcription factor, orchestrates diurnal variability in myocardial injury. Unexpectedly, BMAL1 modulates circadian-dependent cardiac injury by forming a transcriptionally active heterodimer with a non-canonical partner, hypoxia-inducible factor 2 alpha (HIF2A)6,21-23, in a diurnal manner. Substantiating this finding, we determined the cryo-EM structure of the BMAL1/HIF2A/DNA complex, revealing a previously unknown capacity for structural rearrangement within BMAL1, which enables the crosstalk between circadian rhythms and hypoxia signaling. Furthermore, we identified amphiregulin (AREG) as a rhythmic transcriptional target of the BMAL1/HIF2A heterodimer, critical for regulating circadian variations of myocardial injury. Finally, pharmacologically targeting the BMAL1/HIF2A-AREG pathway provides effective cardioprotection, with maximum efficacy when aligned with the pathway's circadian trough. Our findings not only uncover a novel mechanism governing the circadian variations of myocardial injury but also pave the way for innovative circadian-based treatment strategies, potentially shifting current treatment paradigms for myocardial infarction.